Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 15 2021 - 4:25PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of November 2021
Commission File Number: 001-39137
AnPac Bio-Medical Science Co., Ltd.
(Registrant’s name)
801 Bixing Street, Bihu County
Lishui, Zhejiang Province 323006
The People’s Republic of China
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): ¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7): ¨
Explanatory Note:
The document attached as exhibit 5.1 to this Form 6-K
is hereby incorporated by reference into the Registrant’s Registration Statement on Form F-3 initially filed with the U.S.
Securities and Exchange Commission on May 28, 2021 (Registration No. 333-256630) and shall be a part thereof from the date on
which this current report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.
On November 15, 2021, AnPac Bio-Medical Science Co., Ltd. (the "Company") closed its previously announced underwritten public offering
of 1,132,111 of its American Depositary Shares ("shares") at a public offering price of $2.22 per share. Gross proceeds before deducting
the underwriting discount and other offering expenses payable by the Company are approximately $2.5 million.
Exhibit Index:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
AnPac Bio-Medical Science Co., Ltd.
|
|
|
|
(Registrant)
|
|
|
|
|
Date: November 15, 2021
|
|
By:
|
/s/ Chris Chang Yu
|
|
|
Name:
|
Dr. Chris Chang Yu
|
|
|
Title:
|
Chairman of the Board of Directors and Chief Executive Officer
|
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Apr 2024 to May 2024
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From May 2023 to May 2024